Baricitinib

Référence M2039-5mg

Conditionnement : 5mg

Marque : AbMole Bioscience

Demander plus d'informations

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

All AbMole products are for research use only, cannot be used for human consumption.

Baricitinib Structure
Synonym:

INCB28050, LY3009104


Quality Control & Documentation
Biological Activity

Baricitinib (formerly INCB28050, LY3009104) is a selective orally bioavailable JAK1/JAK2 inhibitor. Baricitinib preferentially inhibits JAK1 and JAK2, with 10-fold selectivity over Tyk2 and 100-fold over JAK3. INCB-28050 (baricitinib) inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 at concentrations <50 nM. Baricitinib also inhibits pSTAT3 stimulated by IL-23 with IC50 of 20 nM in isolated naive T-cells. Baricitinib (INCB028050) was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. Baricitinib reduces levels of pSTAT3 in a dose- and time-dependent manner in the peripheral blood of rAIA animals. INCB28050 (Baricitinib) (10 mg/mL, p.o.) improves a composite score of joint damage by 47% in the murine CIA model.

Chemical Information
Molecular Weight 371.42
Formula C16H17N7O2S
CAS Number 1187594-09-7
Solubility (25°C) DMSO 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Fridman JS, et al. J Immunol. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
M1575-10mg
 10mg 
orb593928-20mg
 20mg